论文部分内容阅读
了解卵巢肿瘤中转移抑制基因ｎｍ２３－Ｈ１的表达情况及其与卵巢癌分级分期、转移预后的关系。应用免疫组化ＡＢＣ方法检测１０３例卵巢癌、８例交界性卵巢肿瘤、３２例良性肿瘤及３０例正常卵巢的ｎｍ２３－Ｈ１蛋白表达，并分析了ｎｍ２３－Ｈ１表达与卵巢癌临床病理学的关系。１）在恶性、交界性和良性卵巢肿瘤及正常卵巢中ｎｍ２３－Ｈ１的表达率分别为７０．９％、６２．５％、５０％和２０％；恶性组与良性组及正常对照组相比有明显统计学差异；２）ｎｍ２３－Ｈ１表达与卵巢癌的组织类型、残存癌灶大小及治疗情况无明显关系，与淋巴结转移及预后相关不显著；而与分级分期明显相关，分化较差、期别较晚的卵巢癌患者的ｎｍ２３－Ｈ１表达明显降低。ｎｍ２３－Ｈ１基因在卵巢肿瘤的发生中起着重要作用，且与卵巢癌的分级分期明显相关
To understand the expression of metastasis suppressor gene nm23-H1 in ovarian cancer and its relationship with staging, metastasis and prognosis of ovarian cancer. Immunohistochemical ABC method was used to detect the expression of nm23-H1 protein in 103 cases of ovarian cancer, 8 cases of borderline ovarian tumor, 32 cases of benign tumor and 30 cases of normal ovary. The relationship between nm23-H1 expression and clinicopathology of ovarian cancer was analyzed. . 1) The expression rates of nm23-H1 in malignant, borderline and benign ovarian tumors and normal ovary were 70.9%, 62.5%, 50%, and 20%, respectively; malignant group was compared with benign group and normal control group. There was a significant statistical difference; 2) The expression of nm23-H1 was not significantly associated with the histological type, residual tumor size, and treatment status of ovarian cancer, and was not significantly associated with lymph node metastasis and prognosis; however, it was significantly associated with graded stage and poorly differentiated. The late stage of ovarian cancer patients with nm23-H1 expression was significantly reduced. The nm23-H1 gene plays an important role in the occurrence of ovarian tumors and is significantly associated with the staging of ovarian cancer.